logo

HALO

Halozyme Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
EPS Below Expectations
Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About HALO

Halozyme Therapeutics, Inc.

A biopharmaceutical company that develops recombinant human enzymes and novel oncology therapies for the tumor microenvironment

Biological Technology
Invalid Date
05/10/2007
NASDAQ Stock Exchange
350
12-31
Common stock
12390 El Camino Real, San Diego, California, 92130
--
Halozyme Therapeutics, Inc., is a biopharmaceutical company founded in 1998. In November 2007, the company was reorganized and registered in Delaware (previously registered in Nevada). The company is committed to the development and commercialization of innovative products. The company studies extracellular matrix, extracellular regions, including cell migration, signaling and survival. Over the years, the company has developed unique scientific expertise that allows it to pursue treatments that focus on environmental development.

Earnings Call

Company Financials

EPS

HALO has released its 2025 Q1 earnings. EPS was reported at 1.11, versus the expected 0.94, beating expectations. The chart below visualizes how HALO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HALO has released its 2025 Q1 earnings report, with revenue of 264.86M, reflecting a YoY change of 35.22%, and net profit of 118.09M, showing a YoY change of 53.72%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime